[Downloaded free from http://www.toxicologyinternational.com on Wednesday, April 27, 2016, IP: 14.139.224.243]

Original Article

Association of Circulating Resistin with Metabolic Risk Factors in Indian Females Having Metabolic Syndrome

A. K. Singh, V. Gupta[1], Vani Gupta, S. Kumar, N. Srivastava, T. Jafar, A. B. Pant[2]

Department of Physiology, Chhatrapati Shahuji Maharaj Medical University, Lucknow, Uttar Pradesh, [1]Department of Obstetrics and Gynecology, Chhatrapati Shahuji Maharaj Medical University, Lucknow, Uttar Pradesh, [2]*In Vitro* Toxicology Laboratory, Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India

ABSTRACT

Role of resistin in insulin sensitivity and metabolic syndrome (MetS) is controversial till date. Increased serum resistin levels are associated with MetS and insulin resistance. The aim of this study was to investigate the relationship between serum resistin levels with markers of the MetS in females. In a cross-sectional study, a total of 170 healthy female subjects were selected for the study. Out of which 71 (age 31.59 ± 4.88 years) were with MetS and 99 (age 31.75 ± 6.34 years) were without MetS. Different parameters of MetS and serum resistin level were measured according to the standard protocols as given in NCEP ATP III 2001 guideline. Serum resistin levels were significantly higher in subjects with MetS when compared with subjects without MetS [13.54 ± 4.14 ng/ml (n = 71) vs. 7.42 ± 2.31 ng/ml (n = 99); $P \leq 0.001$]. Resistin levels were positively associated with waist circumference, systolic and diastolic blood pressure, plasma glucose, waist/hip ratio, serum triglycerides, serum cholesterol, serum VLDL, plasma insulin, and insulin resistance, while it was negatively associated with high-density lipoprotein. This study demonstrates a positive correlation between resistin and factors of MetS except high-density lipoprotein which was found to be negatively correlated in Indian female subjects.

Key words: Insulin resistance, metabolic syndrome, resistin

INTRODUCTION

Resistin is a circulating protein of 114 amino acids which belongs to the resistin-like family.[1,2] Resistin is regulated by insulin, glucose, growth hormone, and thiazolidinediones.[3-6] The role of resistin in humans is not very clear till now. Studies with rodents have suggested resistin protein as a link between obesity, insulin resistance, and diabetes.[7-9] In humans, data on the role of resistin in insulin sensitivity and obesity are still controversial.[10] Increased resistin levels were found in mice with diet-induced obesity and in ob/ob mice.[1] Studies suggested that mice injected with recombinant resistin or overexpressing resistin protein had impaired glucose tolerance and insulin action.[11-13] It was found that human hepatic cells overexpressing resistin had impaired glucose uptake and glycogen synthesis.[14] It was positively correlated with proinflammatory factors in adults with pathophysiological conditions such as atherosclerosis, renal disease, and inflammation of respiratory tracts.[15-22] Resistin is clearly involved in inflammation but its specific function in that situation remains to be clarified. Because of its link with obesity, inflammation, and insulin resistance, resistin has been tagged as a potential metabolic syndrome (MetS) marker. Supporting this theory, adults with MetS tend to have higher resistin levels than their healthy counterparts.[23] However, the correlation between insulin resistance and resistin in adult humans remains

Access this article online

Quick Response Code:

Website: www.toxicologyinternational.com

DOI: 10.4103/0971-6580.84272

Address for correspondence: Dr. Vani Gupta, Department of Physiology, Chhatrapati Shahuji Maharaj Medical University, Lucknow - 226 003, Uttar Pradesh, India. E-mail: vaniphysiology@gmail.com

[Downloaded free from http://www.toxicologyinternational.com on Wednesday, April 27, 2016, IP: 14.139.224.243]

controversial, supported by some studies[24-26] while opposed by some other workers,[27-29] therefore, proven weak correlation between resistin and MetS. Some authors indicated that increased serum resistin levels were associated with increased obesity, visceral fat,[1,30,31] insulin resistance, and type 2 diabetes,[15] while other groups failed to observe such correlations.[22,32-34] Furthermore, the contribution of resistin to the MetS is still under investigation.[35,36] The aim of this study was to investigate the correlation between serum resistin levels with the markers of MetS in Indian female subjects.

MATERIALS AND METHODS

Study design

This is a cross-sectional case–control study, conducted in north Indian adult females with age between 20 and 40 years. We enrolled 170 adult women for this study. A structured proforma was filled to collect the information regarding their medical, personal, family, and dietary history. This study was approved by the ethical committee of our institute and "we certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research." Written informed consent was obtained from all the participants. This study was conducted under the principles of the Declaration of Helsinki.

All the subjects were diagnosed according to the NCEP ATP III criteria for MetS.[37] Samples were divided into two group: study group and control group. Study group composed of 71 human female subjects having MetS (mean age 31.59 ± 4.88 years) and control group composed of 99 healthy human female subjects without MetS (mean age 31.75 ± 6.34 years) who were non-alcoholic, non-diabetic, and without any kind of cardiac, respiratory, inflammatory, and metabolic diseases. All samples were collected from Lucknow and nearby areas.

Anthropometric measurements

All the subjects were evaluated; in addition to waist hip ratio (WHR) (a good marker for measuring central/visceral obesity), the following anthropometric parameters, body mass index (BMI), height (Ht.), weight (Wt.), waist circumference (WC), blood pressure (BP), and pulse rate (PR), were also measured. BMI was calculated as weight (in kilograms) divided by square of height (in meters).

Biochemical measurements

Blood samples for biochemical parameters were collected from subjects in the morning having 12 h fast. Serum and plasma were separated from 3.0 ml of blood. Estimation of plasma glucose was done by GOD-POD method (Randox Laboratories Ltd., Antrim, UK) and serum lipid profile was done by enzymatic method (Randox Laboratories Ltd.). Plasma insulin was estimated by Immuno-radiometric assay method (Immunotech Radiova, Prague). Subsequently, insulin resistance was calculated by homeostatic model assessment index[38] using the equation:

HOMA Index = [fasting Insulin (μU/I) × fasting glucose (mmol/l)/22.5]

Determination of serum resistin levels

Resistin concentration in plasma was measured by using sandwich ELISA assay kit (Biovendor Research and Diagnostic Products, Czech Republic), according to the manufacturer's protocol. In brief, plasma samples were diluted into 1:3 ratios with dilution buffer. The lowest detectable amount of the human resistin protein was 0.1 ng/ml having interassay variability of 5.1% and intraassay variability of 2.8%. For this analysis, aliquots of plasma kept at -20°C were thawed and processed in single time.

Statistical analysis

All the clinical data and anthropometric values are presented as mean ± SD. Statistical analysis was conducted by using SPSS Version 11.0 for windows. Comparisons between groups were made by using Student's *t*-test. For all analyses, *P* value <0.05 was considered as statistically significant.

RESULTS

Characteristics of subjects with and without MetS are shown in Table 1. The subjects with MetS were well overweight (BMI 28.93 ± 3.85 kg/m^2) when compared with the subjects without MetS (22.63 ± 4.05 kg/m^2, $P \leq 0.001$; Table 1). Serum resistin levels were found significantly ($P < 0.05$) higher in subjects with MetS when compared with subjects without MetS (13.53 ± 4.11 ng/ml vs. 7.42 ± 2.31 ng/ml, $P \leq 0.001$; Table 1). Serum resistin levels were not correlated with the age of the subjects. We observed a significant difference in levels of all the biochemical parameters and anthropometrical measurements [Tables 1 and 2]. Factors of MetS were significantly higher in the cases compared with controls, viz., WC (91.69 ± 13.41 vs. 75.63 ± 12.46, $P \leq 0.001$), systolic and diastolic blood pressure (128.33 ± 10.76 vs. 119.26 ± 8.2, $P \leq 0.001$ and 87.18 ± 7.19 vs. 80.95 ± 6.71, $P \leq 0.001$), triglyceride (TG) levels (171.86 ± 70.59 vs. 106.35 ± 40.98 mg/dl, $P \leq 0.0001$), high-density lipoprotein (HDL) level (40.48 ± 6.85 vs. 50.08 ±.6.67 mg/dl, $P \leq 0.001$), and glucose concentration (107.89 ± 20.41 vs. 91.47 ± 15.68 mg/dl, $P \leq 0.001$) [Table 2]. Anthropometrical measurements were also significantly higher in subjects with MetS when compared with the subjects without MetS (BMI 28.93 ± 3.85 vs. 22.63 ± 4.05 kg/m^2, $P \leq 0.001$; weight 68.68 ± 8.09 vs. 53.72 ± 9.64 kg, $P \leq$

[Downloaded free from http://www.toxicologyinternational.com on Wednesday, April 27, 2016, IP: 14.139.224.243]

Table 1: Demographic characteristics and biochemical parameters summary (Mean ± SD) of control and cases

Variables	Control (n=99)	Cases (n=71)	*P* value
Age (yrs)	31.75± 6.33	31.59 ± 4.88	NS
Height (cm)	154.16 ± 6.33	154.29 ± 6.02	NS 0.89
Weight (kg)	53.72± 9.64	68.68 ± 8.09	<0.001
BMI (kg m^{-2})	22.63 ± 4.05	28.93 ± 3.85	<0.001
HC (cm)	90.56±9.1	96.52 ± 7.88	<0.001
WHR	0.83±.08	0.94± 0.10	<0.001
FPI (µU/ml)	6.52 ± 1.73	12.53±4.55	<0.001
HOMA-IR	1.47±0.46	3.44±1.77	<0.001
Resistin (ng/ml)	7.42 ± 2.31	13.53 ± 4.11	<0.001
TC (mg/dl)	155.28 ± 45.01	173.83 ± 41.34	<0.0001
VLDL (mg/dl)	21.27 ± 8.21	34.37 ± 14.11	<0.0001
LDL (mg/dl)	94.89 ± 52.89	98.97 ± 41.61	NS
TC/ HDL	3.56 ± 1.32	4.43 ± 1.35	<0.0001
HDL/ LDL	0.60 ± 0.36	0.47± 0.22	<0.009
LDL/HDL	2.22± 1.48	2.55± 1.20	NS

BMI- Body Mass Index; HC- Hip Circumference; WHR- Waist to Hip Ratio; IR-Insulin Resistance; TC-Total Cholesterol; VLDL- Very Low Density Lipoprotein; LDL- Low Density Lipoprotein; FPI- Fasting Plasma Insulin; HOMA-Homeostasis Model Assessment

Table 2: Summary of parameters of metabolic syndrome (Mean ± SD) of control and cases

Variables	Control (n=99)	Cases (n=71)	*P* value
WC (cm)	75.63± 12.46	91.69 ± 13.41	<0.0001
Systolic BP	119.26 ± 8.2	128.33 ±10.76	<0.0001
Diastolic BP	80.95 ± 6.71	87.18 ± 7.19	<0.001
Glucose	91.47 ± 15.68	107.89 ± 20.41	<0.0001
TG	106.35±40.98	171.86 ± 70.59	<0.0001
HDL cholesterol	50.08±.6.67	40.48± 6.85	<0.0001

0.001; WHR 0.94 ± 0.10 vs. 0.83 ± 0.08 m, $P \leq 0.001$). On performing Pearson correlation to quantify that how biochemical parameters like TG, WC, HDL and Glucose levels are correlated to resistin, we obtained that TG, WC and Glucose were positively where as HDL was negatively correlated with resistin [Figure 1].

DISCUSSION

Our present investigation showed the higher serum resistin levels in the Indian females with MetS (cases) when compared with controls (females without MetS) and well correlated with the factors of MetS such as fasting plasma glucose, TG, systolic and diastolic blood pressure and WC [Figure 1]. Further, these findings were also correlated with various biochemical parameters such as total cholesterol and VLDL levels as well as physiological parameters such as BMI, hip circumference, and WHR in the female subjects. Serum resistin level negatively correlated with HDL level.

Most of the anthropometric parameters, factors of MetS, and biochemical parameters as depicted in Table 1 and 2, have shown significant differences between cases and controls. Serum resistin levels were also significantly higher in the subjects with MetS when compared with subjects without MetS (13.53 ± 4.11 ng/ml vs. 7.42 ± 2.31 ng/ml, $P \leq 0.001$; Table 1). We also found a significant correlation of between serum resistin levels with BMI. Same types of the results were also reported by some workers[21,22]; however, some showed negative findings.[39-43] It has been reported that resistin is associated with low HDL in a smaller number of healthy and T2DM subjects.[44,45] The serum resistin levels were also found associated with serum concentrations of TG and BMI.[46] The serum resistin levels were inversely




Figure 1: Relationship (Pearson correlation) of serum resistin (ng/ml) with (a) WC (cm), (b) fasting plasma glucose (mg/dl), (c) serum TG level, and (d) with serum HDL (mg/dl) level in cases of Indian females aged between 20 and 40 years. It is positively correlated with TG, fasting plasma glucose and WC.

[Downloaded free from http://www.toxicologyinternational.com on Wednesday, April 27, 2016, IP: 14.139.224.243]

associated with serum concentrations of HDL-cholesterol which was in agreement with the previous report of Osawa *et al.* who have reported an inverse correlation of resistin with HDL in the Japanese general population.[47] Furuhashi *et al* revealed that circulating resistin was not correlated with blood pressure. These resistin levels were not very different among controls and cases with essential hypertension with or without insulin resistance; however, our results suggest a positive correlation between serum resistin levels with SBP and DBP.[48] Recently, Norata and their colleagues reported that serum resistin levels were higher in females with MetS in a population-based study including 1090 subjects and mimicking our results.[49] Although, our study was mainly confined toward the physical measurements and biochemical parameters. Menzaghi and their colleagues have reported the genetic correlations of resistin with BMI, WC, and homeostasis model assessment of insulin resistance (HOMA-IR) index.[24]

In conclusion, we found that resistin levels were associated with metabolic and anthropometric parameters in cases with MetS. Furthermore, an extensive study is needed to establish these correlations between resistin and factors of MetS.

ACKNOWLEDGMENTS

Financial support to this work was provided by the Indian Council of Medical Research, New Delhi (ICMR 5/10/2/2006-RHN).

REFERENCES

1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, *et al.* The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
2. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13:18-23.
3. Kawashima J, Tsuruzoe K, Motoshima H, Shirakami A, Sakai K, Hirashima Y, *et al*. Insulin down-regulates resistin mRNA through the synthesis of protein(s) that could accelerate the degradation of resistin mRNA in 3T3-L1 adipocytes. Diabetologia 2003;46:231-40.
4. Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, *et al.* Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002;51:1737-44.
5. Delhanty PJ, Mesotten D, McDougall F, Baxter RC. Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology 2002;143:2445-8.
6. Wolfing B, Neumeier M, Buechler C, Aslanidis C, Scholmerich J, Schaffler A. Interfering effects of insulin, growth hormone and glucose on adipokine secretion. Exp Clin Endocrinol Diabetes 2008;116:47-52.
7. Juan CC, Au LC, Fang VS, Kang SF, Ko YH, Kuo SF, *et al.* Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001;289:1328-33.
8. Le Lay S, Boucher J, Rey A, Castan-Laurell I, Krief S, Ferre P, *et al*. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 2001;289:564-7.
9. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, *et al*. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferatoractivated receptor gamma agonists. J Biol Chem 2001;276:25651-3.
10. Ukkola O. Resistin – a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002;147:571-4.
11. Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003;285:E106-15.
12. Palanivel R, Sweeney G. Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Lett 2005;579:5049-54.
13. Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 2006;49:183-90.
14. Sheng CH, Di J, Jin Y, Zhang YC, Wu M, Sun Y, *et al.* Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine 2008;33:135-43.
15. Harsch IA, Koebnick C, Wallaschofski H, Schahin SP, Hahn EG, Ficker JH, *et al.* Resistin levels in patients with obstructive sleep apnoea syndrome-the link to subclinical inflammation? Med Sci Monit 2004;10:CR510-5.
16. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.
17. Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist FL, *et al.* Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate, inflammation, but not with insulin resistance. Kidney Int 2006;69:596-604.
18. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, *et al.* Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005;29:1315-20.
19. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin, resistin levels in relation to metabolic factors, inflammatory markers, vascular reactivity in diabetic patients, subjects at risk for diabetes. Diabetes Care 2004;10:2450-7.
20. Al-Daghri N, Chetty R, McTernan PG, Al-Rubean K, Al-Attas O, Jones AF, *et al.* Serum resistin is associated with C-reactive protein and LDL cholesterol in type 2 diabetes, coronary artery disease in a Saudi population. Cardiovasc Diabetol 2005;4:10.
21. Stejskal D, Adamovska S, Bartek J, Jurakova R, Proskova J. Resistin concentrations in persons with diabetes mellitus of type 2 and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:63-9.
22. Filippidis G, Liakopoulos V, Mertens PR, Kiropoulos T, Stakias N, Verikouki C, *et al.* Resistin serum levels are increased but not correlated with insulin resistance in chronic hemodialysis patients. Blood Purif 2005;23:421-8.
23. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between serum resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008;57:494-501.
24. Menzaghi C, Coco A, Salvemini L, Thompson R, De Cosmo S, Doria A, *et al.* Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic

[Downloaded free from http://www.toxicologyinternational.com on Wednesday, April 27, 2016, IP: 14.139.224.243]

Caucasians. J Clin Endocrinol Metab 2006;91:2792-5.
25. Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol 2006;5:10.
26. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006;91:64-8.
27. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, *et al.* Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003;88:5452-5.
28. Kunnari A, Ukkola O, Kesaniemi YA. Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients. Diabet Med 2005;22:583-9.
29. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, *et al.* Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004;89:1844-8.
30. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, *et al*. Increased serum resistin in adults with prader-willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 2005;90:4335-40.
31. Matsuda M, Kawasaki F, Yamada K, Kanda Y, Saito M, Eto M, *et al*. Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. Diabet Med 2004;21:881-8.
32. Farvid MS, Ng TW, Chan DC, Barrett PH, Watts GF. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 2005;7:406-13.
33. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, *et al*. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005;48:2330-3.
34. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 2005;52:519-24.
35. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, *et al*. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
36. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109:42-6.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
38. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing Insulin Resistance among obese children and adolescents. Pediatrics 2005;115:e500-3.
39. Cho YM, Youn BS, Chung SS, Kim KW, Lee HK, Yu KY, *et al*. Common genetic polymorphisms in the promoter of resistin gene are major determinants of serum resistin concentrations in humans. Diabetologia 2004;47:559-65.
40. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, *et al*. Enzyme-linked immunosorbent assay for circulating human resistin: Resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004;339:57-63.
41. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, *et al*. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848-56.
42. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, *et al*. Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88:6098-106.
43. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, *et al*. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes J Clin Endocrinol Metab 2004;89:150-6.
44. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. Serum resistin level among healthy subjects: Relationship to anthropometric and metabolic parameters. Metabolism 2005;54:471-5.
45. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-7.
46. Asano H, Izawa H, Nagata K, Nakatochi M, Kobayashi M, Hirashiki A, *et al*. Plasma resistin concentration determined by common variants in the resistin gene and associated with metabolic traits in an aged Japanese population. Diabetologia 2010;53:234-46.
47. Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, *et al*. Plasma resistin, associated with single nucleotide polymorphism – 420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 2007;30:1501-6.
48. Furuhashi M, Ura N, Higashiura K, Murakami H, Shimamoto K. Circulating resistin levels in essential hypertension. Clin Endocrinol 2003;59:507-10.
49. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156:279-84.

How to cite this article: Singh AK, Gupta V, Gupta V, Kumar S, Srivastava N, Jafar T, Pant AB. Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. Toxicol Int 2011;18:168-72.

Source of Support: Indian Council of Medical Research, New Delhi (ICMR 5/10/2/2006-RHN). **Conflict of Interest:** None declared.